IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy

被引:76
|
作者
Humbert, Marc [1 ]
Bousquet, Jean [2 ]
Bachert, Claus [3 ,4 ,5 ]
Palomares, Oscar [6 ]
Pfister, Pascal [7 ]
Kottakis, Ioannis [7 ]
Jaumont, Xavier [7 ]
Thomsen, Simon Francis [8 ,9 ]
Papadopoulos, Nikolaos G. [10 ,11 ]
机构
[1] Hop Bicetre, Serv Pneumol, 78 Rue Gen Leclerc, F-94270 Le Kremlin Bicetre, France
[2] MACVIA France, Contre Malad Chron Vieillissement Actif France, European Innovat Partnership Act & Hlth Ageing Re, Montpellier, France
[3] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium
[4] Univ Ghent, Dept Otorhinolaryngol, Ghent, Belgium
[5] Ghent Univ Hosp, Ghent, Belgium
[6] Univ Complutense Madrid, Dept Biochem & Mol Biol, Sch Chem, Madrid, Spain
[7] Novartis Pharma AG, Basel, Switzerland
[8] Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark
[9] Univ Copenhagen, Dept Biomed Sci, Copenhagen, Denmark
[10] Univ Manchester, Div Infect Immun & Resp Med, Manchester, Lancs, England
[11] Univ Athens, Allergy Dept, Pediat Clin 2, Athens, Greece
关键词
Omalizumab; Asthma; Multimorbidities; Treatment; Allergic rhinitis; Rhinoconjunctivitis; Chronic rhinosinusitis with nasal polyps; Vernal keratoconjunctivitis; Food allergies; Allergic bronchopulmonary aspergillosis; RAPID ORAL DESENSITIZATION; ATOPIC-DERMATITIS; ANTI-IGE; BRONCHOPULMONARY ASPERGILLOSIS; VERNAL KERATOCONJUNCTIVITIS; CHRONIC RHINOSINUSITIS; FOOD ALLERGY; CASE SERIES; DOUBLE-BLIND; MAST-CELLS;
D O I
10.1016/j.jaip.2019.02.030
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Allergic asthma often coexists with different pathological conditions, called multimorbidities, that are mostly of allergic nature and share a common underlying inflammatory pathophysiological mechanism. Multimorbidities of allergic asthma may influence asthma control, its severity, and patients' response to treatment, and contribute to the overall socioeconomic burden of the disease. Immunoglobulin E (IgE) is known to play a central role in the pathogenesis of various allergic diseases, including asthma. Thus, IgE-mediated immunologic pathways present an attractive target for intervention in asthma and multimorbidities. In this review, we discuss the most frequently reported IgE-mediated multimorbidities in allergic asthma, including allergic rhinitis, rhinoconjunctivitis, atopic dermatitis, vernal keratoconjunctivitis, chronic rhinosinusitis with nasal polyps, food allergies, and allergic bronchopulmonary aspergillosis. Omalizumab is a recombinant humanized monoclonal antibody against IgE and has been in use to treat allergic asthma for more than a decade. We comprehensively review the clinical evidence for omalizumab in the treatment of the aforementioned multimorbidities in allergic asthma. (C) 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.
引用
收藏
页码:1418 / 1429
页数:12
相关论文
共 50 条
  • [1] Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma
    Bousquet, J.
    Siergiejko, Z.
    Swiebocka, E.
    Humbert, M.
    Rabe, K. F.
    Smith, N.
    Leo, J.
    Peckitt, C.
    Maykut, R.
    Peachey, G.
    [J]. ALLERGY, 2011, 66 (05) : 671 - 678
  • [2] Omalizumab in the management of patients with allergic (IgE-mediated) asthma
    Sandstrom, Thomas
    [J]. JOURNAL OF ASTHMA AND ALLERGY, 2009, 2 : 49 - 62
  • [3] Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma
    Milgrom, Henry
    Fowler-Taylor, Angel
    Vidaurre, Carlos Fernandez
    Jayawardene, Sumedha
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (01) : 163 - 169
  • [4] Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma
    Kulus, M.
    Hebert, J.
    Garcia, E.
    Taylor, A. Fowler
    Vidaurre, C. Fernandez
    Blogg, M.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (06) : 1285 - 1293
  • [5] Improvements in asthma control and quality of life with omalizumab in allergic (IgE-mediated) asthma patients
    Braunstahl, Gert-Jan
    Deenstra, Marco
    Canvin, Janice
    Georgiou, Panos
    Peachey, Guy
    Chen, Chien-Wei
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [6] Omalizumab therapy reduces asthma exacerbations and is rated as effective by physicians in children with severe allergic (IgE-mediated) asthma
    Kulus, M.
    Hebert, J.
    Garcia, E.
    Taylor, A. F.
    Vidaurre, C. F.
    Blogg, M.
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2009, 39 (12): : 1952 - 1952
  • [7] Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients
    Siergiejko, Zenon
    Swiebocka, Ewa
    Smith, Nicola
    Peckitt, Clare
    Leo, Jo
    Peachey, Guy
    Maykut, Robert
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (11) : 2223 - 2228
  • [8] Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma
    Lanier, Bob
    Bridges, Tracy
    Kulus, Marek
    Taylor, Angel Fowler
    Berhane, Indrias
    Vidaurre, Carlos Fernandez
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 124 (06) : 1210 - 1216
  • [9] Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE
    Lowe, Philip J.
    Renard, Didier
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (02) : 306 - 320
  • [10] Omalizumab Improves Patient-Reported Outcomes In Patients With Allergic (IgE-mediated) Asthma
    Yang, W. H.
    Georgiou, P.
    Canvin, J.
    Chen, C.
    Peachey, G.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB147 - AB147